FinTechFunding

Starpharma: Updates market on nasal spray

  • Starpharma has provided updates on its COVID-19 nasal protection spray, which uses antiviral dendrimer SPL7013
  • Already the company has identified a manufacturer and device components, undertook pilot manufacturing, and compiled regulatory documents
  • Depending on discussions with regulators, Starpharma expects to accelerate approval of a SPL7013 nasal spray
  • SPL7013 works by blocking the interaction between viral surface proteins and human cell receptor proteins
  • Further, Starpharma hasn’t ruled out other applications for SPL7013, such as injection, ocular (through the eye), or mist inhalation
  • Starpharma is currently up a steady 9.52 per cent and shares are trading for $1.15 each
Previous article
Metalicity: Confirms further high-grade gold at Liepold
Next article
Scentre Group: Posts $3.66B loss in 1HFY20
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Kraken Parent Acquires Bitnomial for $550M, Strengthening Crypto Offerings

This acquisition marks a significant expansion into derivatives trading.Highlights: Kraken's parent company announces $550M acquisition of Bitnomial.Bitnomial is...
FinTech

NatWest Group Strengthens Free Investment Guidance Programme

New initiative aims to educate more customers on investing.Highlights: NatWest Group expands free investment guidance programme.Initiative targets educating...
FinTech

Tether Launches New Stablecoin Wallet to Enhance User Experience

This innovative platform aims to improve accessibility for crypto users.Highlights: Tether has introduced a new stablecoin wallet.The wallet...
FinTech

FCA Strengthens Money Laundering Combat with Synthetic Dataset

New collaboration aims to enhance detection capabilities against financial crime.Highlights: FCA partners with Turing Institute to combat money...